Clinical Outcome Assessments Toolbox for Radiopharmaceuticals

For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The NCI's planned scope for HRQOL, symptom...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Capala, Jacek, Dicker, Adam P., Movsas, Benjamin, Ivy, Susan Percy, Minasian, Lori M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795707/
https://www.ncbi.nlm.nih.gov/pubmed/31649885
http://dx.doi.org/10.3389/fonc.2019.01028
Descripción
Sumario:For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The NCI's planned scope for HRQOL, symptom and patient-reported outcomes management research is explained as it pertains to radiopharmaceutical clinical development. An effort already underway to support protocol authoring via an NCI Cancer Therapy Evaluation Program (CTEP) Centralized Protocol Writing Service (CPWS) is described as this service aids incorporation of HRQOL, symptom and patient-reported outcomes management research into sponsored protocols.

Ejemplares similares